Clin2Atlas
AtlasCancersNeoplasms

Breast cancer

3Curable in someAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020251989 — Goserelin approved (FDA)1992 — Paclitaxel approved (FDA)1995 — Docetaxel anhydrous approved (FDA)1995 — Dexrazoxane approved (FDA)1995 — Anastrozole approved (FDA)1996 — Gemcitabine approved (FDA)1996 — Ibandronic acid approved (FDA)1996 — Toremifene approved (FDA)1997 — Letrozole approved (FDA)1997 — Raloxifene approved (FDA)1998 — Capecitabine approved (FDA)1998 — Trastuzumab approved (FDA)1999 — Exemestane approved (FDA)1999 — Epirubicin approved (FDA)2002 — Fulvestrant approved (FDA)2004 — Bevacizumab approved (FDA)2007 — Ixabepilone approved (FDA)2007 — Lapatinib approved (FDA)2009 — Everolimus approved (FDA)2010 — Eribulin approved (FDA)2010 — Denosumab approved (FDA)2012 — Pertuzumab approved (FDA)2013 — Trastuzumab emtansine approved (FDA)2013 — Technetium tc 99m tilmanocept approved (FDA)2014 — Olaparib approved (FDA)2015 — Palbociclib approved (FDA)2016 — Atezolizumab approved (FDA)2017 — Neratinib approved (FDA)2017 — Abemaciclib approved (FDA)2017 — Ribociclib approved (FDA)2018 — Talazoparib approved (FDA)2019 — Alpelisib approved (FDA)2019 — Trastuzumab deruxtecan approved (FDA)2020 — Tucatinib approved (FDA)2020 — Sacituzumab govitecan approved (FDA)2020 — Fluoroestradiol approved (FDA)2020 — Margetuximab approved (FDA)2023 — Elacestrant approved (FDA)2023 — Capivasertib approved (FDA)2024 — Inavolisib approved (FDA)
1989: Drug approval — Goserelin approved (FDA). 1992: Drug approval — Paclitaxel approved (FDA). 1995: Drug approval — Docetaxel anhydrous approved (FDA). 1995: Drug approval — Dexrazoxane approved (FDA). 1995: Drug approval — Anastrozole approved (FDA). 1996: Drug approval — Gemcitabine approved (FDA). 1996: Drug approval — Ibandronic acid approved (FDA). 1996: Drug approval — Toremifene approved (FDA). 1997: Drug approval — Letrozole approved (FDA). 1997: Drug approval — Raloxifene approved (FDA). 1998: Drug approval — Capecitabine approved (FDA). 1998: Drug approval — Trastuzumab approved (FDA). 1999: Drug approval — Exemestane approved (FDA). 1999: Drug approval — Epirubicin approved (FDA). 2002: Drug approval — Fulvestrant approved (FDA). 2004: Drug approval — Bevacizumab approved (FDA). 2007: Drug approval — Ixabepilone approved (FDA). 2007: Drug approval — Lapatinib approved (FDA). 2009: Drug approval — Everolimus approved (FDA). 2010: Drug approval — Eribulin approved (FDA). 2010: Drug approval — Denosumab approved (FDA). 2012: Drug approval — Pertuzumab approved (FDA). 2013: Drug approval — Trastuzumab emtansine approved (FDA). 2013: Drug approval — Technetium tc 99m tilmanocept approved (FDA). 2014: Drug approval — Olaparib approved (FDA). 2015: Drug approval — Palbociclib approved (FDA). 2016: Drug approval — Atezolizumab approved (FDA). 2017: Drug approval — Neratinib approved (FDA). 2017: Drug approval — Abemaciclib approved (FDA). 2017: Drug approval — Ribociclib approved (FDA). 2018: Drug approval — Talazoparib approved (FDA). 2019: Drug approval — Alpelisib approved (FDA). 2019: Drug approval — Trastuzumab deruxtecan approved (FDA). 2020: Drug approval — Tucatinib approved (FDA). 2020: Drug approval — Sacituzumab govitecan approved (FDA). 2020: Drug approval — Fluoroestradiol approved (FDA). 2020: Drug approval — Margetuximab approved (FDA). 2023: Drug approval — Elacestrant approved (FDA). 2023: Drug approval — Capivasertib approved (FDA). 2024: Drug approval — Inavolisib approved (FDA)

What's being tested now

2000: 2 trials started2001: 3 trials started2002: 4 trials started2003: 6 trials started2004: 2 trials started2005: 2 trials started2006: 2 trials started2007: 5 trials started2008: 4 trials started2009: 7 trials started2010: 10 trials started2011: 12 trials started2012: 11 trials started2013: 16 trials started2014: 25 trials started2015: 20 trials started2016: 25 trials started2017: 51 trials started2018: 50 trials started2019: 75 trials started2020: 109 trials started2021: 192 trials started2022: 256 trials started2023: 353 trials started2024: 575 trials started2025: 741 trials started2026: 679 trials started2000201020202026741

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 3055 active Breast cancer trials on Clin2 →

Related

Lip and oral cavity cancerNasopharynx cancerOther pharynx cancerEsophageal cancerStomach cancerColon and rectum cancerGallbladder and biliary tract cancerPancreatic cancerLarynx cancerTracheal, bronchus, and lung cancerMalignant skin melanomaSoft tissue and other extraosseous sarcomas

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.